Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma - PubMed (original) (raw)
. 2003 Dec;201(4):589-95.
doi: 10.1002/path.1474.
Affiliations
- PMID: 14648662
- DOI: 10.1002/path.1474
Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma
Raúl Cassia et al. J Pathol. 2003 Dec.
Abstract
Cyclin E overexpression occurs in a subset of endometrial carcinomas (ECs), but the molecular mechanisms underlying this alteration remain to be established. The present study has analysed amplification of the cyclin E gene (CCNE) and mutation in hCDC4, the gene coding for the F-box protein, which tags phosphorylated cyclin E for proteosomal degradation, to ascertain whether these alterations might be responsible for cyclin E overexpression in ECs. Cyclin E and p53 expression was studied by immunohistochemistry in eight atypical endometrial hyperplasias (AEHs), 51 endometrioid endometrial carcinomas (EECs), and 22 non-endometrioid endometrial carcinomas (NEECs). CCNE amplification was analysed by fluorescence in situ hybridization (FISH). Mutations in exons 2-11 of the hCDC4 gene were screened by PCR-SSCP-sequencing. Finally, the polymorphic marker D4S1610 was used to assess loss of heterozygosity (LOH) in the hCDC4 gene. Cyclin E overexpression was found in 26/81 (32%) cases and was associated with the histological type of the lesion, since it was not found in any AEHs but was present in 27% of EECs and 54.5% of NEECs (p=0.035). Cyclin E overexpression was associated with histological grade (p=0.011) and p53 immunostaining in EECs (p=0.033). CCNE amplification was found in 6 of 37 (16%) ECs examined. There was a significant association between CCNE amplification and the histological type of the lesion, since five (83%) of the six cases with amplification were NEECs (p=0.008). One EEC harboured an hCDC4 mutation: a CGA to CAA (Arg/Gln) change at codon 479. In addition, D4S1610 LOH was found in 7 of 23 (30%) informative cases analysed, but no correlation with cyclin E overexpression was found. However, the tumour with hCDC4 mutation also showed LOH. This is the first study demonstrating that cyclin E overexpression is associated with gene amplification in ECs, these alterations being more frequent in NEECs. Although hCDC4 exhibits a low mutation frequency in ECs overexpressing cyclin E, it seems to function as a tumour suppressor gene that is involved in endometrial carcinogenesis.
Copyright 2003 John Wiley & Sons, Ltd.
Similar articles
- CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
Nakayama K, Rahman MT, Rahman M, Nakamura K, Ishikawa M, Katagiri H, Sato E, Ishibashi T, Iida K, Ishikawa N, Kyo S. Nakayama K, et al. Int J Oncol. 2016 Feb;48(2):506-16. doi: 10.3892/ijo.2015.3268. Epub 2015 Nov 26. Int J Oncol. 2016. PMID: 26647729 Free PMC article. - Molecular alterations associated with cyclin D1 overexpression in endometrial cancer.
Moreno-Bueno G, Rodríguez-Perales S, Sánchez-Estévez C, Marcos R, Hardisson D, Cigudosa JC, Palacios J. Moreno-Bueno G, et al. Int J Cancer. 2004 Jun 10;110(2):194-200. doi: 10.1002/ijc.20130. Int J Cancer. 2004. PMID: 15069681 - hCDC4 gene mutations in endometrial cancer.
Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, Marth C, Widschwendter M, Reed SI. Spruck CH, et al. Cancer Res. 2002 Aug 15;62(16):4535-9. Cancer Res. 2002. PMID: 12183400 - The Fbxw7/hCdc4 tumor suppressor in human cancer.
Tan Y, Sangfelt O, Spruck C. Tan Y, et al. Cancer Lett. 2008 Nov 18;271(1):1-12. doi: 10.1016/j.canlet.2008.04.036. Epub 2008 Jun 9. Cancer Lett. 2008. PMID: 18541364 Review. - [Function and mechanism of tumor suppressor gene FBW7 in tumorigenesis].
Huang HJ, Zheng F, Xu FP, Liu YH, Zhuang HG. Huang HJ, et al. Zhonghua Bing Li Xue Za Zhi. 2013 Mar;42(3):214-6. doi: 10.3760/cma.j.issn.0529-5807.2013.03.020. Zhonghua Bing Li Xue Za Zhi. 2013. PMID: 23769449 Review. Chinese. No abstract available.
Cited by
- CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A, Kuhn E, Wu RC, Ogawa H, Bahadirli-Talbott A, Mao TL, Sugimura H, Shih IM, Wang TL. Ayhan A, et al. Mod Pathol. 2017 Feb;30(2):297-303. doi: 10.1038/modpathol.2016.160. Epub 2016 Oct 21. Mod Pathol. 2017. PMID: 27767100 - The genomics and genetics of endometrial cancer.
O'Hara AJ, Bell DW. O'Hara AJ, et al. Adv Genomics Genet. 2012 Mar;2012(2):33-47. doi: 10.2147/AGG.S28953. Adv Genomics Genet. 2012. PMID: 22888282 Free PMC article. - FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein.
Song Y, Zhou X, Bai W, Ma X. Song Y, et al. Tumour Biol. 2015 Jun;36(6):4197-202. doi: 10.1007/s13277-015-3056-4. Epub 2015 Jan 14. Tumour Biol. 2015. PMID: 25586348 - FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation.
Babaei-Jadidi R, Li N, Saadeddin A, Spencer-Dene B, Jandke A, Muhammad B, Ibrahim EE, Muraleedharan R, Abuzinadah M, Davis H, Lewis A, Watson S, Behrens A, Tomlinson I, Nateri AS. Babaei-Jadidi R, et al. J Exp Med. 2011 Feb 14;208(2):295-312. doi: 10.1084/jem.20100830. Epub 2011 Jan 31. J Exp Med. 2011. PMID: 21282377 Free PMC article. - Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.
Wang J, Wang H, Peters M, Ding N, Ribback S, Utpatel K, Cigliano A, Dombrowski F, Xu M, Chen X, Song X, Che L, Evert M, Cossu A, Gordan J, Zeng Y, Chen X, Calvisi DF. Wang J, et al. J Hepatol. 2019 Oct;71(4):742-752. doi: 10.1016/j.jhep.2019.05.027. Epub 2019 Jun 11. J Hepatol. 2019. PMID: 31195063 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous